Two of the most common reasons people visit a urologist are actually hematuria (blood in the urine) and recurrent urinary tract infections (rUTIs) in women. In 2025, the American Urological Association (AUA) released major updates to its clinical guidelines for both conditions, fundamentally changing how doctors evaluate and manage them. These changes mean fewer invasive procedures for low-risk patients, better options for preventing infections, and more personalized care overall.
Many patients with cystitisor bladder inflammation wonder whether their symptoms could be something more serious – understanding cystitis causes and treatment is an important first step. For women who suffer from repeated infections, getting to the root cause of recurrent UTIs can make all the difference.
What Is Hematuria and Who Gets It?
Hematuria simply means red blood cells in the urine. When you can see the blood pink, red, or cola-colored urine it’s called gross hematuria. When blood is only visible under a microscope, it’s called microscopic hematuria. Microscopic hematuria affects about 6.5% of the general population. Among patients referred for a full evaluation, only about 1% to 10% turn out to have cancer.
Most people with microscopic hematuria have no symptoms at all. The condition is often discovered during a routine checkup. Because many patients are never referred for a full evaluation, the updated 2025 AUA guideline takes a more precise, risk-based approach to decide who needs further testing.
The 2025 AUA Hematuria Guideline: A New Three-Tier Risk System
The 2025 AUA Microhematuria Guideline was formally amended on February 27, 2025. The most important change is the introduction of a refined three-tier risk-stratification system: low/negligible, intermediate, and high risk.
Clinicians now classify patients based on individual risk factors for bladder cancer:
- Age and sex
- Smoking history (pack-years)
- Degree of hematuria (number of red blood cells per high-power field, or RBC/HPF)
- History of gross hematuria
- Occupational chemical exposures
- Prior pelvic radiation or chemotherapy
In a large validation study involving 15,779 patients with hematuria, the cancer detection rates were 0.4% for low-risk, 1.0% for intermediate-risk, and 2.6% for high-risk microscopic hematuria. For low-risk patients, the rate is so low (0% to 0.4%) that the category was renamed low/negligible risk.
What Changed for Low/Negligible-Risk Patients?
For patients classified as low/negligible risk, the updated guideline makes a major shift toward observation. These patients should have a repeat urinalysis within six months rather than immediate cystoscopy or imaging. If the repeat test is still positive for hematuria, the patient is re-assessed and may be reclassified.
This change helps prevent unnecessary invasive procedures for the large number of people who will never develop cancer.
What About Intermediate- and High-Risk Patients?
For intermediate-risk patients, cystoscopy and imaging are generally recommended. For high-risk patients, prompt cystoscopy and appropriate upper tract imaging (such as CT urography) are indicated. The 2025 updates also clarify that patients on anticoagulation therapy should receive the same hematuria evaluation as those not on anticoagulation.
New Urinary Biomarkers for Hematuria Evaluation
The 2025 AUA hematuria guideline expands the role of urinary biomarkers – tests that look for specific proteins, DNA changes, or RNA patterns in urine to help rule out cancer without an invasive procedure.
The updated guideline now provides clearer guidance on when to use tests such as FISH (fluorescence in situ hybridization), NMP22, and Cxbladder. For example, Cxbladder Triage is now mentioned specifically in the 2025 guidelines as a tool that can help rule out urothelial carcinoma in low- and intermediate-risk patients, potentially avoiding unnecessary procedures.
Advanced diagnostic tools are especially important in women’s urology care, where symptoms can sometimes overlap with other conditions.
Recurrent UTIs in Women: Major Guideline Changes
Recurrent urinary tract infections (rUTIs) affect millions of women. Nearly one-third of women who experience a UTI will have another one within six months. On September 4, 2025, the AUA, in collaboration with the Canadian Urological Association (CUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released a comprehensive amendment to the recurrent uncomplicated UTI guideline.
This update represents a paradigm shift moving away from simply trying to eliminate all bacteria and toward a focus on symptom relief, antimicrobial stewardship, and non-antibiotic prevention strategies.
Redefining Success: Symptom Resolution Over Microbial Eradication
Treatment success should be defined as symptom resolution, not microbial eradication. Many women have bacteria in their urine without any symptoms (asymptomatic bacteriuria), and treating it with antibiotics does not help and may cause harm.
Non-Antibiotic Prophylaxis Options
For women with rUTIs, clinicians are now advised to offer several non-antibiotic strategies, including:
- Cranberry products – the recommendation was upgraded from “may” to “should” offer cranberry for UTI prophylaxis
- Methenamine Hippurate – an antiseptic that works in the urine without using traditional antibiotics
- Increased water intake – for patients with low daily water intake (below 1.5 liters or 50 ounces per day)
Vaginal estrogen remains a recommended option for perimenopausal and postmenopausal women with rUTIs. D-mannose alone may not be effective.
If you experience urinary urgency or urge incontinence, it is important to distinguish between a simple UTI and a more complex bladder condition like overactive bladder.
How These Changes Affect Your Care at Adult & Pediatric Urology
At Adult & Pediatric Urology , our physicians apply the latest evidence to your care:
- If you have microscopic hematuria and are at low/negligible risk, we may recommend a repeat urinalysis in six months rather than immediate cystoscopy.
- If you are a woman with recurrent UTIs, we will discuss non-antibiotic prevention options such as cranberry, methenamine, increased water intake, or vaginal estrogen.
Our commitment is to provide effective care that minimizes unnecessary interventions.
Frequently Asked Questions (FAQ)
I was told I have microscopic hematuria. Do I really need a cystoscopy?
Not necessarily. If you are at low or negligible risk, the 2025 AUA guideline recommends repeating the urinalysis within six months instead of immediate cystoscopy. Your urologist will help determine your risk level.
What does “low/negligible risk“ mean?
It means your chance of having bladder cancer is very low, less than 1 percent. This category includes women under 60, men under 40, never-smokers, and patients with only a few red blood cells on a single test.
What non-antibiotic options work best for preventing recurrent UTIs?
The strongest evidence supports cranberry products, methenamine hippurate, and increased water intake of at least 1.5 liters per day. Vaginal estrogen is also recommended for perimenopausal and postmenopausal women.
Does the new guideline mean I should never take antibiotics for a UTI?
No. Antibiotics remain the standard treatment for acute, symptomatic UTIs. The change focuses on avoiding antibiotics for asymptomatic bacteriuria and using non-antibiotic options for prevention.
How do I know if I am at low, intermediate, or high risk for hematuria?
Your urologist will assess your age, smoking history, degree of hematuria, and other risk factors. At Adult & Pediatric Urology, we will explain your risk level and what it means for your evaluation.
Medical Disclaimer
The information provided in this article is for educational purposes only and does not substitute professional medical advice. Always consult a licensed healthcare provider for diagnosis and treatment recommendations specific to your situation. If you have visible blood in your urine, persistent pain, or fever, seek medical attention promptly.
Author
Jerome P. Keating, M.D. – Urologist at Adult & Pediatric Urology. Dr. Keating specializes in general urology and has a particular interest in guideline-based care for hematuria and urinary tract infections.
References
- AUA News – Microscopic Hematuria Guideline Amendment: Refined risk stratification and introduction of urinary biomarkers (2025)
- AUA – Recurrent Uncomplicated Urinary Tract Infections in Women Guideline Amendment (September 4, 2025)
- UroToday – AUA 2025 Hematuria Guidelines: Overview and risk stratification (SUO 2025 recap)
- Guideline Central – AUA Microhematuria Guideline Summary (February 27, 2025)